EDMONTON, June 17 /CNW/ - Isotechnika Inc. (TSX:ISA) announced today that
the Company will web cast its Annual General and Special Meeting in Edmonton
on Thursday, June 19, 2008 at 12:00 p.m. ET/10:00 a.m. MT. The web cast will
include corporate and scientific updates. The web cast will be chaired by Dr.
Robert Foster, Isotechnika's Chairman & CEO.
Interested parties will be able to access the live web cast by logging on
to the Company's Web site at www.isotechnika.com. A recording of the web cast
will be archived for a 90 day period through the web cast archives at
www.newswire.ca and on the Company's Web site.
About Isotechnika Inc.
Edmonton-based Isotechnika Inc. is an international biopharmaceutical
company focused on the discovery and development of novel immunosuppressive
therapeutics that are designed to offer advantages over other currently
available treatments. There is a significant unmet medical need in the
treatment of both solid organ transplantation and autoimmune disease. It is
estimated that the market potential exceeds $2 billion annually in sales for
calcineurin inhibitors such as voclosporin.
Voclosporin is a next generation calcineurin inhibitor, which recently
completed a Phase 2b North American trial for the prevention of kidney
rejection following transplantation. An extension to the Phase 2b trial and a
combined Phase 3 European/Canadian trial for the treatment of moderate to
severe psoriasis are ongoing. Our partner, Lux Biosciences, is currently
conducting three separate Phase 2/3 pivotal trials investigating voclosporin
(referred to as LX211 by Lux) for the treatment of uveitis. Voclosporin has
also entered First-in-Man trials as the drug utilized in the CINATRA(TM) Drug
Coated Coronary Stent system developed by the Company's partner, Atrium
Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can be found
This press release may contain forward-looking statements.
Forward-looking statements, including the Company's belief as to the potential
of its products, the Company's expectations regarding the issuance of
additional patents and the Company's ability to protect its intellectual
property, involve known and unknown risks and uncertainties, which could cause
the Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include, among
others, the availability of funds and resources to pursue research and
development projects, the ability to economically manufacture its products,
the potential of its products, the success and timely completion of clinical
studies and trials, the Company's ability to successfully commercialize its
products, the ability of the Company to defend its patents from infringement
by third parties, and the risk that the Company's patents may be subsequently
shown to be invalid or infringe the patents of others. Investors should
consult the Company's quarterly and annual filings with the Canadian
commissions for additional information on risks and uncertainties relating to
the forward-looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements.
For further information:
For further information: Stephanie Gillis-Paulgaard, Director, Corporate
Communications, Isotechnika Inc., Phone: (780) 909-4661, Fax: (780) 484-4105,